APLP2 and familial pancreatic carcinoma: However, APP appears to be a poor target for secretases expressed in pancreatic cancer cell lines, as evidenced by minimal expression of APP C-terminal fragments in the majority of pancreatic cancer cell lines (Fig. 1A) and failure of APLP2 reduction (by siRNA or β-secretase inhibitors) to enhance APP C-terminal cleavage (data not shown).